Ayala Pharmaceuticals Inc (ADXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 10-2022 | 09-2022 | 07-2022 | 06-2022 | 04-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,359 | -28,246 | -9,768 | -18,061 | -2,805 |
| Depreciation Amortization | 473 | 121 | 435 | 81 | 317 |
| Accounts receivable | N/A | -129 | N/A | -262 | N/A |
| Accounts payable and accrued liabilities | N/A | -888 | N/A | 40 | N/A |
| Other Working Capital | 313 | -131 | -1,368 | -425 | -1,608 |
| Other Operating Activity | -1,711 | 2,931 | -1,606 | 1,620 | -4,360 |
| Operating Cash Flow | $-15,284 | $-26,342 | $-12,307 | $-17,007 | $-8,456 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 35 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -201 | N/A | -201 | N/A | -135 |
| Other Investing Activity | -201 | 0 | -201 | 0 | -135 |
| Investing Cash Flow | $-166 | $N/A | $-201 | $N/A | $-135 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 512 | N/A | 44 | N/A |
| Other Financing Activity | -956 | 0 | -956 | 0 | -938 |
| Financing Cash Flow | $-956 | $512 | $-956 | $44 | $-938 |
| Beginning Cash Position | 41,614 | 37,339 | 41,614 | 37,339 | 41,614 |
| End Cash Position | 25,208 | 11,509 | 28,150 | 20,376 | 32,085 |
| Net Cash Flow | $-16,406 | $-25,830 | $-13,464 | $-16,963 | $-9,529 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,284 | -26,342 | -12,307 | -17,007 | -8,456 |
| Free Cash Flow | -15,284 | -26,342 | -12,307 | -17,007 | -8,456 |